The Lancet Oncology 'Under Review': What Each Status Means

The journal publishes no status-by-status durations, so the durations below are unofficial planning estimates.

Before the paper reaches external reviewers, a Lancet handling editor at The Lancet Oncology evaluates whether the practice-changing and global-oncology relevance warrants Lancet Oncology's selective editorial slots. The journal publishes no desk-rejection rate; the Lancet group's editorial policies say a high proportion of submissions are rejected on in-house assessment alone. A desk rejection can mean the handling editor concluded that the work would fit better at another Lancet title or that the global-oncology audience appeal is uncertain.

The journal's information for authors lists what a submission should include: a covering letter, the manuscript including tables and panels, figures, an author statement form, declaration of interests and source of funding statements, protocols and CONSORT details for randomised controlled trials, and a Research in context panel for all primary research Articles. The journal requires registration of all interventional trials. Figures are supplied separately, not embedded.

The handling editor reads the paper and evaluates editorial triage for practice-changing and global-oncology relevance. Lancet's editorial guidance explicitly cites these criteria.

The Lancet group's editorial policies say that after peer review, research articles are discussed among editors of the same journal or at a multi-disciplinary editorial meeting, and that editors may also discuss which Lancet journal a research paper will be best suited to. The journal does not describe a parallel meeting during the desk screen or a number of days it adds.

Lancet handling editors at The Lancet Oncology usually invite three clinical or subject-based experts plus a statistical reviewer (the information for authors says at least two reviewers and a statistician).

Once reviewers agree to review, reviewer comments are sent to authors anonymously, unless peer reviewers wish to have their names shared. Reviewers critique the manuscript, make suggestions for improvements, and give recommendations to the authors and the editors, and they are specifically asked to check the content and accuracy of the Research in context panel.

After reports return, the handling editor synthesizes them. If extensive revisions are required, the revised manuscript may be shared with peer reviewers for further comment. The decision to publish remains with the editor.

• Rejection within 1 to 5 days: Administrative issue or immediate scope mismatch.

• Rejection within 1 to 3 weeks: Handling editor desk rejection. Most rejections happen here.

• Still Under Review after 3 weeks: Strong signal. Paper passed the steepest Lancet filter.

• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the submission portal is appropriate.

• Status changes to "Reports Received": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from Lancet Oncology authors during the active editorial window. The journal publishes no median review time, so elapsed time alone does not signal a problem. Reports may already be in editorial synthesis with the handling editor preparing a recommendation. Most reviewer-driven delays come from reviewer-recruitment timing for the multi-reviewer assembly (clinical or subject experts plus a statistical reviewer) rather than slow reviews.

If the portal still says Under Review at the 8-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the handling editor granted it. This is normal practice at Lancet.

During the 5-to-8-week window, the useful distinction is whether the editor needs new information. A short Editorial Manager note is reasonable for a trial-registration correction, ethics update, related-paper disclosure, data-sharing correction, meeting embargo issue, or fast-track context that changed after submission. A general timeline request is better held until week 8 because the most likely bottleneck is reviewer assembly or statistical-review synthesis.

If your Lancet Oncology paper is rejected after review, the natural cascade depends on what the reviewers and handling editor cited:

eClinicalMedicine is the most natural Lancet cascade for clinical-oncology papers with strong evidence but narrower global-oncology framing. Transfers to another Lancet journal take place only with the author's agreement, and where relevant the original peer review comments may also be transferred.

Lancet Regional Health (Americas, Europe, Western Pacific, Southeast Asia, Africa) is the Lancet cascade for regional-focused oncology papers where the regional health-systems framing fits better than the global-oncology Lancet Oncology bar.

JAMA Oncology is a JAMA Network cascade option for clinical-oncology papers where the JAMA Network reach is preferred. JAMA Network operates independently from Lancet; reports do not transfer.

Annals of Oncology is the ESMO cascade option for European-oncology-focused work where the European clinical framing is stronger than global health.

The journal does not publish a reviewer checklist; the four areas below are a Manusights reading of what Lancet reviewers focus on. The table below maps each to actionable preparation.

In our pre-submission work with Lancet Oncology manuscripts, three patterns generate the most consistent reviewer concerns we see at The Lancet Oncology. The recurring issue is not only whether the trial, cohort, or oncology analysis is well run. It is whether the abstract, Research in Context, and statistical package make the same global-oncology claim before reviewers need to reconstruct it.

High-income-country framing flagged for global-oncology fit. When the introduction frames the work around high-income-country treatment patterns without global-oncology generalization, Lancet reviewers consistently flag global-relevance concerns. The strongest manuscripts frame around global-health-oncology contexts.

Check your global-oncology framing →

Statistical analysis plan under-documented. When the pre-specified statistical analysis plan is thin or post-hoc analyses are not clearly distinguished from pre-specified analyses, the Lancet statistical reviewer consistently requests expanded methods documentation. The usual reviewer assembly (three clinical or subject experts and a statistical reviewer) means statistical scrutiny is independent of clinical-relevance review.

Check your statistical methods and SAP alignment →

Lancet venue mismatch flagged by handling editor. When the handling editor concludes the work is sound but the practice-changing or global-oncology framing is uncertain, transfer offers to eClinicalMedicine or Lancet Regional Health are common. Lancet editors take these transfers seriously.

Check your Lancet Oncology versus Lancet family route →

We have reviewed 50+ manuscripts targeting The Lancet Oncology, Lancet, JAMA Oncology, Annals of Oncology, and Journal of Clinical Oncology. The recurring Lancet Oncology miss is not simply clinical quality; it is that the first page does not prove why the result matters to an international oncology audience now. Papers with credible trials, strong cohorts, or useful biomarkers can still feel too local, too disease-siloed, or too statistically under-specified for the Lancet reviewer assembly.

In our pre-submission review work across clinical-oncology and high-impact medical targets, we see five recurring preventable risks: global relevance framed after the results instead of in the opening, SAP and post-hoc analysis boundaries left implicit, trial-registration deviations explained late, subgroup claims stronger than the interaction evidence, and data-sharing or Research in Context language that does not match the actual contribution.

This is an internal Manusights review sample, not Lancet outcome data, so we use it to identify preventable author-side risks rather than to predict acceptance.

Source limitation: official guidance explains Lancet author rules, editorial policies, and timeline signals, but it does not show private handling-editor notes, statistical-review comments, or the reason a specific manuscript is still in Editorial Manager. That is why this page separates public status interpretation from manuscript-specific readiness signals.

The most useful Lancet Oncology preparation is a first-page and statistical-readiness audit. We check whether the abstract names the clinical decision, whether Research in Context explains what the study changes, whether the statistical package can survive independent statistical review, and whether the transfer path would be eClinicalMedicine, Lancet Regional Health, JAMA Oncology, or Annals of Oncology if the editor likes the study but not the fit.

Manusights does not train AI models on customer manuscripts; we do not train on private author files. Eligible paid manuscript reviews include the 60-day money-back guarantee, which matters for unpublished trial data and embargo-sensitive oncology work.

This page was created from Lancet Oncology's public author guidance at thelancet.com and information-for-authors PDF, Lancet editorial documentation (fast-track 3-5 day review and 10-week publication, and the usual model of three clinical or subject-based experts plus a statistical reviewer), and Manusights pre-submission review experience with Lancet Oncology-targeted manuscripts.

For the Lancet oncology landscape beyond The Lancet Oncology, see eClinicalMedicine (broader open-access Lancet), Lancet Regional Health titles (regional focus), and sister oncology titles (JAMA Oncology, Annals of Oncology, JCO, Cancer Discovery). The choice across these titles depends on whether the central contribution is practice-changing-global-oncology (Lancet Oncology), broader-clinical-oncology (eClinicalMedicine), regional-oncology (Lancet Regional Health), JAMA-Network-clinical (JAMA Oncology), European-clinical (Annals of Oncology), or ASCO-treatment-guideline (JCO).

Reviewers at The Lancet Oncology typically include 3 clinical or subject-based experts plus 1 statistical reviewer. The statistical reviewer reviews independently of the clinical reviewers. Preparing a response template that addresses both clinical and statistical perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Lancet Oncology practice-changing-plus-global-oncology bar before submission, our Lancet Oncology pre-submission diagnostic flags the framing weaknesses and reporting-checklist gaps most likely to surface in reviewer reports.